To test whether pharmacological treatment is able to revert these behavioral abnormalities indicative for mental disorders, we tested an in vivo inhibitor of the LPA‐synthesizing enzyme autotaxin (PF8380) which has a nanomolar potency and can be applied orally or by injection to the periphery (Gierse et al, 2010). This evidence concerns the gene ENPP2 and mental disorder.